For operating partners · Mid-market PE & growth equity
You can’t sell it. You won’t kill it.
Now what?
An evidence-scored diagnostic for the software companies you’ve held 4+ years. It finds the blockage, prices the fix, and clears it.
You’ll speak to a founder — no BD team, no follow-up sequence.
BUILT & SOLD AIMBRAIN — ACQUIRED BY BIOCATCH, ACQUIRED BY VISA FOR $2.4B
OPERATED AT
Your book
Your book is aging faster than it’s distributing.
52%
of buyout-backed companies are past year four — the middle of your book among them
<15%
distributions as a share of NAV, four years running — what your LPs keep seeing
3–8
companies per operating partner — attention follows the fee maths
PORTFOLIO OPS NORM
The exit window is open — for companies that are ready. The rest wait, and the waiting is priced.
The alternatives
Every route serves the ends of the book. TRAC is built for the middle.
Who this is for
You can name these companies without opening the fund model.
NOT FOR: DISTRESSED · PRE-REVENUE · COMPOUNDING ON PLAN. THEN WE’RE THE WRONG CALL — AND WE’LL SAY SO.
The TRAC method
Four questions. Scored 0–4. No averaging.
T
Transfer
Does work move cleanly between functions?
R
Roles
Does every function have a real owner?
A
Absorption
Could you absorb double the volume tomorrow?
C
Commitments
Are you selling only what you can deliver?
No averaging. 4·4·4·1 performs like a 1 — growth is lost at the worst gap.
Records over opinions. Every score cites a record. A missing artefact is itself a 0.
The engagement
One Screen ranks the book. Then we fix them one at a time.
What changes
What this changes on your side of the table.
A sequenced path to distributions
Which companies can be made sellable, in what order, at what cost.
Evidence that survives IC
Independent scores, cited to records.
Coverage past the fee maths
Senior-operator attention for the middle of the book.
Exit-ready twelve months early
The precondition for sale, secondary, or CV.
Founders
The diagnosing operators are the implementing operators.
TRAC isn’t delivered through leverage. The two people who score the company are the two people who clear the blockage.
- COO through AimBrain’s acquisition
- Global pre-sales at BioCatch
- Built Keyless’s professional services
- EMEA GTM at Arkose Labs
- Founded AimBrain (BGF-backed); sold to BioCatch
- Forbes 30 Under 30 — Technology
- Principal PM at Tractable
- Wrote the first-ten-enterprise-customers playbook
SEVEN-PLUS YEARS WORKING AS A PAIR, INCLUDING AN EXIT
WHERE WE’VE OPERATED: AIMBRAIN · BIOCATCH · KEYLESS · ARKOSE LABS · TRACTABLE · CIRCUIT MIND · ACCENTURE
Book
Bring us the two companies you’d nominate first.
Thirty minutes with a founder. Describe the book; we’ll tell you honestly whether a Screen would pay.
Prefer email? hello@techtrac.co